Medication info

Janusitin M Tablet 50/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride with Colloidal Anhydrous Silica›1010mg / 1 tablet
Manufacturer / importer
(Co., Ltd.) Hanmi Pharm Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
30 tablets/box[(10 tablets/PTP x 3)]
Approval status
Active

MFDS item code 202200114 · Approved 2022.01.06

Summary

Main use
Improvement of blood glucose control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this product for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This product is generally taken 2 times daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this product should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this product is 1 tablet of 50/500 mg 2 times daily. The dose may be increased to 1 tablet of 50/1000 mg 2 times daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this product (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this product is sitagliptin 50 mg 2 times daily (total daily dose of 100 mg) and the patient's existing metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this product may start at their existing doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with concomitant metformin and sulfonylurea therapy, metformin and insulin therapy, or metformin and thiazolidinedione therapy: The initial dose of this product is sitagliptin 50 mg 2 times daily (total daily dose of 100 mg). The initial dose of metformin should be determined based on the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When this product is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this product in patients previously treated with other oral antihyperglycemic agents. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This product may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this product, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg 2 times daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this product should be discontinued immediately. Patients with hepatic impairment This product should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Ingredients

Manufacturer
(Co., Ltd.) Hanmi Pharm Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in type 2 diabetes mellitus

  • Difficulty in blood glucose control in patients with type 2 diabetes
View approved original text

This medication is used in conjunction with dietary and exercise therapy to help control blood sugar levels in patients with type 2 diabetes. It can be used in cases where previous diabetes medication therapy has not been experienced and blood sugar control is difficult with monotherapy. Additionally, it may be used as an alternative if treatment with metformin or sitagliptin alone is insufficient or if the two medications cannot be combined. This medication helps improve blood glucose control when used in combination with metformin and sulfonylurea, or metformin and thiazolidinedione when those therapies are ineffective. It is also used to enhance treatment effectiveness when blood glucose control remains difficult even after combination therapy with insulin and metformin. Thus, this medication aids in improving blood glucose control at various stages of treatment.

How to take

Adult dose

The dose of this product for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This product is generally taken 2 times daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this product should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this product is 1 tablet of 50/500 mg 2 times daily. The dose may be increased to 1 tablet of 50/1000 mg 2 times daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this product (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this product is sitagliptin 50 mg 2 times daily (total daily dose of 100 mg) and the patient's existing metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this product may start at their existing doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with concomitant metformin and sulfonylurea therapy, metformin and insulin therapy, or metformin and thiazolidinedione therapy: The initial dose of this product is sitagliptin 50 mg 2 times daily (total daily dose of 100 mg). The initial dose of metformin should be determined based on the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When this product is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this product in patients previously treated with other oral antihyperglycemic agents. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This product may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this product, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg 2 times daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this product should be discontinued immediately. Patients with hepatic impairment This product should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Precautions

This medication contains both sitagliptin and metformin and is used for diabetes treatment. When taking this medication, serious allergic reactions may occur, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck appear, discontinue use immediately and consult a physician. There is also a risk of acute pancreatitis, which is inflammation of the pancreas; therefore, if abdominal pain, vomiting, or nausea occur after taking this medication, immediately inform healthcare professionals. Patients with significantly reduced kidney function or conditions that may affect kidney function, such as heart failure, acute myocardial infarction, or severe infections, should not use this medication. It is also unsafe for women who are pregnant or may become pregnant, as well as for breastfeeding women. This medication may lead to a rare but serious side effect called lactic acidosis, so it is important to undergo regular kidney function tests and blood tests. If dehydration, severe vomiting, or diarrhea occurs, stop taking the medication. Care should be taken as hypoglycemia may occur in individuals with high levels of physical activity, irregular eating patterns, or those taking other blood sugar lowering agents. Alcohol consumption should be avoided while taking this medication, and it should be temporarily discontinued prior to any scheduled surgeries, confirming that kidney function is normal before resuming. Additionally, because this medication may interact with other drugs, inform healthcare professionals of any other medications being taken. Elderly patients should exercise more caution as kidney function may decline, and regular kidney function tests should be conducted. It is important to immediately consult a physician if any unusual symptoms or suspected side effects occur.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 22 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • dermatitis
  • anorexia
  • weight loss
  • dyspnea
  • unstable angina
  • dizziness
  • acute kidney failure
  • decreased appetite
  • gastrointestinal disturbance
  • itching

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air exposure, at room temperature between 1°C and 30°C. Proper storage will maintain the drug's effectiveness and allow for safe use.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

30 tablets/box[(10 tablets/PTP x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.